Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations

Diabetes and Metabolism

Volumn 30, Issue 3 III, 2004, Pages

  Puel, J ^a   Valensi, P ^b   Vanzetto, G ^a   Lassmann Vague, V ^b   Monin, J L ^a   Moulin, Ph ^b   Ziccarelli, Ch ^c   Mayaudon, H ^b   Ovize, M ^a   Bernard, S ^b   Van Belle, E ^a   Halimi, S ^b  

^a Societe Francaise de Cardilogie   (France)

^b ALFEDIAM   (France)

^c Natl Coll of French Cardiologists ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROMA; CARDIOVASCULAR RISK; CORONARY RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EXERCISE TEST; FOLLOW UP; GLUCOSE BLOOD LEVEL; GOOD CLINICAL PRACTICE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HIGH RISK PATIENT; HUMAN; METABOLIC DISORDER; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REINFORCEMENT; REVIEW; RISK BENEFIT ANALYSIS; SCINTIGRAPHY; SCREENING TEST; STRESS ECHOCARDIOGRAPHY;

DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 3142763015     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Passa Ph, Drouin P, Issa-Sayegh M, et al. Coronaires et diabète. Recommandations de l'Alfediam. Diabetes Metab, 1995, 21, 446-51.
2. American Diabetes Association. Consensus development conference on the diagnosis of coronary artery disease in people with diabetes. Diabetes Care, 1998, 21, 1551-9.
3. Grundy SM, Howard B, Smith S et al. Prevention conference VI. Diabetes and cardiovascular disease. Circulation, 2002, 105, 2231-9.
4. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercice testing. JACC, 1997, 30, 260-315.
5. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Recommandations ANAES. Diabetes Metab, 1999, 25 (Suppl.2), 1-64.
6. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1998, 21 (Suppl), S5-19.
7. Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death in US. Diabetes Care, 2001, 24, 447-53.
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (adult treatment panel III). JAMA, 2001, 285, 2486-97.
9. The European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab, 2002, 28, 364-76.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projection. Diabetes Care, 1998, 21, 1414-31.
11. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol, 2002, 156, 714-9.
12. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care, 1998, 21, 1138-45.
13. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 1999, 100, 1134-46.
14. American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care, 1993, 19 (2 Suppl), 72-8.
15. Melchior T, Kober L, Madsen CR, et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Eur Heat J, 1999, 20, 973-8.
16. Cosson E, Guimfack M, Paries J, et al. Prognosis for coronary stenoses in patients with diabetes and myocardial ischemia. Diabetes Care, 2003, 26, 1313-4.
17. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation, 1996, 94, 1818-25.
18. Chen J, Radfort MJ, Wang Y, Krumholz HM. Care and outcome of elderly patients with acute myocardial infarction by physician specialty: the effects of comorbidity and functional limitations. Am J Med, 2000, 108, 460-9.
19. Tauber G, Winkelmann BR, Schleifer T, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J, 2003, 145, 285-9.
20. Kannel WB, Mc Gee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA, 1979, 241.
21. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-years cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care, 1993, 16, 434-44.
22. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339, 229-34.
23. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort study. B Med J, 2002, 324, 939-42.
24. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J, 2003, 24, 1406-13.
25. Vlietstra RE, Kronmal RA, Lie JT, et al. Factors affecting the extend and severity of coronary artery disease in patients enrolled in the coronary artery surgery study. Atherosclerosis, 1982, 2, 208-15.
26. Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol, 2002, 40, 946-53.
27. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilatation in no-insulin-dependant diabetes. J Am Coll Cardiol, 1996, 27, 567-74.
28. Knobler H, Savion N, Shenkman, et al. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Throm Res, 1998, 90, 181-90.
29. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetes compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation, 1998, 97, 2213-21.
30. Nitenberg A, Ledoux S, Valensi P, et al. Impairment of coronary microvascular dilatation in response to pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes, 2001, 50, 1180-5.
31. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 2003, 26, 1895-901.
32. Cohn PF. Should silent ischemia be treated in asymptomatic individuals? Circulation, 1990, 82(Suppl II), 149-54.
33. Koïstinen MJ. Prevalence of asymptomatic myocardial ischemia in diabetics subjects. Br Med J, 1990, 301, 92-5.
34. Langer A, Freeman MR, Josse RG, et al. Detection of myocardial ischemia in diabetes mellitus. Am J Cardiol, 1991, 67, 1073-8.
35. Milan study on atherosclerosis and diabetes (MiSAD) group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risks factors in noninsulin-dependent diabetes mellitus. Am J Cardiol, 1997, 79, 134-9.
36. Valensi P, Sachs RN, Lormeau B, et al. Silent myocardial ischemia and left ventricular hypertrophy in diabetic patients. Diabetes Metab, 1997, 23, 409-16.
37. Janand-Delenne B, Savin B, Habib G, et al. Silent myocardial ischemia in patients with diabetes. Who to screen. Diabetes Care, 1999, 22, 1396-400.
38. Weiner DA, Ryan TJ, Parsons L, et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus. A report from coronary artery surgery study (CASS) registry. Am J Cardiol, 1991, 68, 729-34.
39. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care, 2001, 24, 339-43.
40. Valensi P. Predictive value of silent myocardial ischemia in diabetic patients. Influence of age. Diabetologia, 2000, 43 (Suppl 1), A61.
41. Vanzetto G, Halimi S, Hammoud T et al. Prediction of cardiovascular events clinically selected high-risk NIDDM patients. Diabetes Care, 1999, 22, 19-26.
42. Janand-Delenne B, Labastie N, Savin B, et al. Poor prognosis of silent myocardial ischemia: a two years follow-up of 203 diabetic patients. Diabetologia, 2000, 43, suppl I.L.
43. Mark DB, Nelson CL, Califf R, et al. Continuing evolution of therapy for coronary artery disease. Initial results from era of coronary angioplasty. Circulation, 1994, 89, 2015-25.
44. Mock MB, Rinqvist I, Fischer L, et al. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation, 1982, 66, 562-8.
45. Murphy ML, Hultgren HN, Detre K, et al. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration Cooperative Study. N Engl J Med, 1977, 297, 621-7.
46. Fuster V, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N engl J Med, 1992, 326, 242-50, 310-8.
47. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation, 1995, 92, 657-71.
48. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001, 104, 365-72.
49. Davies MJ. The composition of coronary artery plaque. N Engl J Med, 1997, 336, 1312-3.
50. Little WC, Constantinescu M, Robert J, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation, 1988, 78, 1157-66.
51. Ojio S, Takatsu H, Tanaka T, et al. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans. Circulation, 2000, 102, 2063-9.
52. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation, 2002, 105, 939-43.
53. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndromes; a three-vessels intravascular ultrasound study. Circulation, 2002, 106, 804-8.
54. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol, 1994, 24, 11-20. Erratum in: J Am Coll Cardiol, 1995, 26, 842.
55. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol, 1994, 24, 11-20. Erratum in: J Am Coll Cardiol, 1995, 26, 842.
56. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol, 1996, 77, 1273-7.
57. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J, 1990, 11, 43-50.
58. Pyörälä K, persen TR, Kjeksus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease: subgroup analysis of the Scandinavian simvastatin survival study. Diabetes Care, 1997, 20, 614-20.
59. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with mow LDL-Clolesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-Cholesterol and triglycerides as risk factors. Circulation, 2002, 105, 1424-8.
60. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled study. Lancet, 2003, 361, 2005-16.
61. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med, 1999, 341, 410-8.
62. Conroy RM, Piörälä K, Fitzgerald AP, et al. Estimation of ten-years risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J, 2003, 24, 897-1003.
63. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-13 (Erratum BMJ, 1999, 318, 29).
64. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-13 (Erratum BMJ, 1999, 318, 29).
65. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, 1755-62.
66. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint committee on prevention, detection, evaluation and treatment of high blood pressure. JNC 7 report. JAMA, 2003, 289, 2560-72.
67. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position statement). Diabetes Care, 1998, (Suppl. 1), S23-S31.
68. Zuanetti G, Latini R, Maggioni AP, et al. Effetc of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation, 1997, 96, 4239-45.
69. Heart outcomes prevention evaluation (HOPE) study investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000, 355, 253-9.
70. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet published online September 1, 2003.
71. Antiplatelet trialist's collaboration. Collaborative overview of randomized trails of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994, 308, 71-2, 81-106.
72. ETDRSInvestigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA, 1992, 268, 1292-300.
73. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 2002, 90, 625-7.
74. Malmberg K, Ryden L, Eferdic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetes patients with acute myocardial infarction (DIGAMI Study); effect on mortality at 1 year. J Am Coll Cardiol, 1995, 26, 57-65.
75. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998, 316, 823-8.
76. Okin PM, Prineas RJ, Grandits G, et al. Heart rate adjustment of exercise-induced ST-segment depression identifies men who benefit from a risk factor reduction program. Circulation, 1997, 96, 2899-904.
77. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-93.
78. Yusuf S, Zucher D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-years results from randomised trials by the coronary artery bypass trialist collaboration. Lancet, 1994, 344, 1116-21.
79. Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol, 2000, 36, 668-73.
80. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic cardiac ischemia pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularisation. JACC, 1995, 26, 594-605.
81. Mak K, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J, 2003, 24, 1087-103.
82. BARI investigators. Seven-years outcome in the Bypass Angioplasty revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol, 2000, 35, 1122-9.
83. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insight from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation, 2001, 104, 533-8.
84. Feit F, Brooks MM, Sopko, G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry. Circulation, 2000, 101, 2795-802.
85. Van Belle E, Abolmaali K, Bauters C, et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol, 1999, 34, 476-85.
86. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol, 1998, 32, 1866-73.
87. Van Belle E, Bauters C, Hubert E, et al. Restenosis rate in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation, 1997, 96, 1454-60.
88. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic substudy. Circulation, 1999, 100, 2477-84.
89. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol, 2000, 15, 922-8.
90. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002, 346, 1773-8.
91. Moses JW, Leon MB, Popma JL, et al. Sirolimus-eluting stent versus standard stent in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349, 1315-23.
92. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA); a randomised controlled trial. Lancet, 2003, 361, 1149-58.
93. Inoguchi T, Yamashita T, Umeda F, et al. High Incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. Diabetes Res clin Pract, 2000, 47, 37-44.
94. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with non-diabetic individuals without and with prior cardiovascular disease. Eur Heart J, 2003, 24, 1406-13.
95. Hu Fb, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med, 2001, 161, 1717-23.
96. Faglia E, Favales F, Calia P, et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from Milan Study on atherosclerosis and diabetes (MiSAD). Diabetes Care, 2002, 25, 2032-6.
97. Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol, 2002, 40, 954-60.
98. Detournay B, Vauzelle-Kervroedan F, Charles MA, et al. Epidemiology, management and costs of type 2 diabetes in France in 1998. Diabetes Metab, 1999, 25, 356-65.
99. Myers RH, Kiely DK, Cupples LA, et al. Parental history is an independent risk factor for coronary artery disease. The Framingham study. Am Heart J, 1990, 120, 963-9.
100. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation, 1998, 97, 1837-47.
101. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002. Guideline update for exercise testing. Summary article. A report of American College of Cardiology/American Heart Association task force on practice guidelines (Committee to update the 1997 exercise testing guidelines). Circulation, 2002, 106, 1883-92.
102. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med, 1992, 326, 381-6.
103. Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral arterial disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J 1990, 120, 1073-7.
104. Darbar D, Gillespie N, Main G, et al. Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. Am J Cardiol, 1996, 78, 736-40.
105. Kuller LH, Velentgas P, Barzilay J, et al. Diabetes mellitus. Subclinical cardiovascular disease and risk of incident of cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol, 2000, 20, 823-9.
106. Ponsonnaille J, Fabry R, Chapou M, et al. Silent ischemic heart diseases in patients with peripheral arterial diseases. Screening and 5-year prognosis in a population of 418 patients. Arch Mal Cœur, 1991, 84, 1407-11.
107. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med, 1997, 157, 1413-8.
108. Rutter MK, Wahid ST, McComb JM, et al. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol, 2002, 40, 56-61.
109. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function? Circulation, 2002, 106, 2085-90.
110. O'Leary DH, Joseph F, Polak JF, et al. For the cardiovascular health study collaborative group. Carotid artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med, 1999, 340, 14-22.
111. Ridker PM, Buring JE, Cook NR, et al. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-years follow-up of 14719 initially healthy American women. Circulation, 2003, 107, 391-7.
112. Maser Re, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 2003, 26, 1895-901.
113. Hosoi M, Sato T, Yamagami K, et al. Impact of diabetes on coronary stenosis and coronary artery calcification detected by electron-beam computed tomography in symptomatic patients. Diabetes Care, 2002, 25, 696-701.
114. Paillole C, Ruiz J, Juliard JM, et al. Non-invasive identification of severe coronary artery disease in patients with long-standing diabetes mellitus. Eur J Med, 1992, 1, 464-8.
115. Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation, 1990, 81, 899-906.
116. Kannel WB, Gordon T, Castelli WP. Electrocardiographic left ventricular hupertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med, 1970, 72, 813-22.
117. Paillole C, Ruiz J, Juliard JM, et al. Detection of coronary artery disease in diabetic patients. Diabetologia, 1995, 38, 726-31.
118. Rubler S, Gerber D, Reitano J, et al. Predictive value of clinical and exercise variable for detection ofcoronary artery disease in men with diabetes mellitus. Am J Cardiol, 1987, 59, 1310-3.
119. Gerson MC Khoury JC, Hertzberf VS, et al. Prediction of coronary artery disease in a population of insulin-requiring diabetic patients: results of an 8-years follow-up study. Am Heart J, 1988, 116, 820-6.
120. Koistinen MJ, Huikuri HV, Pirttiaho H, et al. Evaluation of exercise electrocardiography and thallium tomographic imaging in detecting asymptomatic coronary artery disease in diabetic patient. Br Heart J, 1990, 63, 7-11.
121. Cosson E, Paycha F, Paries J, et al. Selecting silent coronary stenosis with stratifying cardiac risk in patients with diabetes. ECG stress test or exercise myocardial scintigraphy. Diabetes Metab (in press).
122. Boudreau RJ, Strony JT, du Cret RP, et al. Perfusion thallium imaging of type 1 diabetes with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology, 1990, 175, 103-5.
123. Kumar R, Patel CD, Marwah A, et al. Detection of coronary artery disease by stress thallium scintigraphy in diabetic patients. Nucl Med Commun, 2001, 22, 287-9.
124. Machecourt J, Longere P, Fagret D, et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. J Am Coll Cardiol, 1994, 23, 1096-106.
125. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1,137 patients with 6-year follow-up. Circulation, 1999, 100, 1521-7.
126. Hachamovitch R, Hayes S, Friedmann JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans. Circulation, 2003, 41, 1329-40.
127. Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J, 1999, 138, 1025-32.
128. Faglia E, Favales F, Calia P, et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care, 2002, 25, 2032-6.
129. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion SPECT in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol, 2002, 90, 827-32.
130. Giri S, Shaw LJ, Murthy DR. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation, 2002, 105, 32-40.
131. Takeishi Y, Chiba J, Abe S, et al. Noninvasive identification of left main and three-vessel coronary artery disease by thallium-201 single photon emission computed tomography during adenosine infusion. Ann Nucl Med, 1994, 8, 1-7.
132. Romanens M, Gradel C, Saner H, et al. Comparison of 99mTc-sestamibi lung/heart ratio, transient ischaemic dilation and perfusion defect size for the identification of severe and extensive coronary artery disease. Eur J Nucl Med, 2001, 28, 907-10.
133. Lebtahi NE, Stauffer JC, Delaloye AB. Left bundle branch block and coronary artery disease: accuracy of dipyridamole thallium-201 single-photon emission computed tomography in patients with exercise anteroseptal perfusion defects. J Nucl Cardiol, 1997, 4, 266-73.
134. Tandogon I, Yetkin E, Yanik A, et al. Comparison of thallium-201 exercise SPECT and dobutamine stress echocardiography for diagnosis of coronary artery disease in patients with left bundle branch block. Int J Cardiovasc Imaging, 2001, 17, 339-45.
135. Elhendy A, van Domburg RT, Poldermans D, et al. Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. Diabetes Care, 1998, 21, 1797-802.
136. Sozzi FB, Elhendy A, Roelandt JR, et al. Prognostic value of dobutamine stress echocardiography in patients with diabetes. Diabetes Care, 2003, 26, 1074-8.
137. Elhendy A, Arruda AM, Mahoney DW. Pronostic stratification of diabetic patient by exercise echocardiography. J Am Coll Cardol, 2001, 37, 1551-7.
138. Shaw LJ, Hachamovitch R, Berman DS, et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study. J Am Coll Cardiol, 1999, 33, 661-9.
139. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report from the American College of Cardiology/American Heart Association task force on practce guidelines. J Am Coll Cardiol, 1999, 33, 2092-197 (Erratum, J Am Coll Cardio, 1999, 34, 314).
140. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report from the American College of Cardiology/American Heart Association task force on practce guidelines. J Am Coll Cardiol, 1999, 33, 2092-197 (Erratum, J Am Coll Cardio, 1999, 34, 314).
141. Schinkel AF, Bax JJ, Geleijnse ML, et al. Noninvasive evaluation of ischaemic heart disease: myocardiol perfusion imaging or stress echocardiography. Eur Heart J, 2003, 24, 789-800.
142. Delahaye F, Bory M, Cohen A, et al. Recommandations de la Société Française de Cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë. Arch Mal Cœur, 2001, 94, 697-725.